-
公开(公告)号：EP4242655A2
公开(公告)日：2023-09-13
申请号：EP23163877.6
申请日：2006-06-08
申请人： Dana-Farber Cancer Institute, Inc. , The Brigham and Women's Hospital, Inc. , Emory University , The President and Fellows of Harvard College
发明人： Barber, Daniel , Wherry, John E. , Freeman, Gordan , Sharpe, Arlene , Dorfman, David M. , Ahmed, Rafi
IPC分类号： G01N33/53
摘要： The present invention provides methods and compositions for the treatment, prevention, or reduction of persistent infections, such as chronic infections, latent infections, and slow infections and cancer. The methods and compositions of the invention are also useful for the alleviation of one or more symptoms associated with such infections and cancer.
-
公开(公告)号：EP4242655A3
公开(公告)日：2024-02-21
申请号：EP23163877.6
申请日：2006-06-08
申请人： Dana-Farber Cancer Institute, Inc. , The Brigham and Women's Hospital, Inc. , Emory University , The President and Fellows of Harvard College
发明人： Barber, Daniel , Wherry, John E. , Freeman, Gordan , Sharpe, Arlene , Dorfman, David M. , Ahmed, Rafi
摘要： The present invention provides methods and compositions for the treatment, prevention, or reduction of persistent infections, such as chronic infections, latent infections, and slow infections and cancer. The methods and compositions of the invention are also useful for the alleviation of one or more symptoms associated with such infections and cancer.
-
3.发明公开METHODS AND COMPOSITIONS FOR THE TREATMENT OF PERSISTENT INFECTIONS AND CANCER BY INHIBITING THE PROGRAMMED CELL DEATH 1 (PD-1)PATHWAY 审中-公开方法和组合物的持续感染和癌症的治疗通过抑制程控1（PD-1）-ZELLTODWEGES
公开(公告)号：EP3130350A1
公开(公告)日：2017-02-15
申请号：EP16187881.4
申请日：2006-06-08
申请人： Dana-Farber Cancer Institute, Inc. , The Brigham and Women's Hospital, Inc. , Emory University , The President and Fellows of Harvard College
发明人： Barber, Daniel , Wherry, John E. , Freeman, Gordan , Sharpe, Arlene , Dorfman, David M. , Ahmed, Rafi
IPC分类号： A61K39/395 , G01N33/53 , C07K16/28
CPC分类号： C07K16/2803 , A61K31/713 , A61K38/1709 , A61K39/39 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61K2039/55516 , A61K2039/55566 , A61K2039/572 , C07K16/2818 , C07K16/2827 , C07K2317/70 , C07K2317/73 , C07K2317/74 , C07K2317/76 , C12N15/1138 , C12N2310/14 , G01N33/5011 , G01N33/505 , G01N33/57484 , G01N33/57492 , G01N2800/26 , Y02A50/412 , Y02A50/467 , Y02A50/58
摘要： The present invention provides methods and compositions for the treatment, prevention, or reduction of persistent infections, such as chronic infections, latent infections, and slow infections and cancer. The methods and compositions of the invention are also useful for the alleviation of one or more symptoms associated with such infections and cancer.
摘要翻译： 本发明提供了用于治疗，预防或减轻持续感染，慢性感染的方法和组合物：如，潜伏性感染，和慢性感染和癌症。 本发明的方法和组合物因此可用于与寻求感染和癌症相关的一种或多种症状的减轻有用。
-
4.发明授权Methods and compositions for the treatment of persistent infections by inhibiting the programmed cell death 1 (PD-1)pathway 有权用于通过抑制程序性细胞死亡1（PD-1）途径来治疗持续感染的方法和组合物
公开(公告)号：EP2397155B1
公开(公告)日：2017-12-13
申请号：EP11162667.7
申请日：2006-06-08
申请人： Dana-Farber Cancer Institute, Inc. , The Brigham and Women's Hospital, Inc. , Emory University , President and Fellows of Harvard College
发明人： Freeman, Gordan , Sharpe, Arlene , Dorfman, David M. , Ahmed, Rafi , Barber, Daniel , Wherry, E. John
CPC分类号： C07K16/2803 , A61K31/713 , A61K38/1709 , A61K39/39 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61K2039/55516 , A61K2039/55566 , A61K2039/572 , C07K16/2818 , C07K16/2827 , C07K2317/70 , C07K2317/73 , C07K2317/74 , C07K2317/76 , C12N15/1138 , C12N2310/14 , G01N33/5011 , G01N33/505 , G01N33/57484 , G01N33/57492 , G01N2800/26 , Y02A50/412 , Y02A50/467 , Y02A50/58
摘要： The present invention provides methods and compositions for the treatment, prevention, or reduction of persistent infections, such as chronic infections, latent infections, and slow infections and cancer. The methods and compositions of the invention are also useful for the alleviation of one or more symptoms associated with such infections and cancer.
-
5.发明授权Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (PD-1)pathway 有权方法和组合物持久性感染和癌症的治疗通过抑制编程1（PD-1）-Zelltodweges
公开(公告)号：EP2397156B1
公开(公告)日：2016-11-02
申请号：EP11162681.8
申请日：2006-06-08
申请人： Dana-Farber Cancer Institute, Inc. , The Brigham and Women's Hospital, Inc. , Emory University , The President and Fellows of Harvard College
发明人： Barber, Daniel , Wherry, E. John , Freeman, Gordan , Sharpe, Arlene , Dorfman, David M. , Ahmed, Rafi
IPC分类号： A61K31/713 , A61K38/17 , A61K39/00 , C07K16/28 , G01N33/50 , G01N33/574
CPC分类号： C07K16/2803 , A61K31/713 , A61K38/1709 , A61K39/39 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61K2039/55516 , A61K2039/55566 , A61K2039/572 , C07K16/2818 , C07K16/2827 , C07K2317/70 , C07K2317/73 , C07K2317/74 , C07K2317/76 , C12N15/1138 , C12N2310/14 , G01N33/5011 , G01N33/505 , G01N33/57484 , G01N33/57492 , G01N2800/26 , Y02A50/412 , Y02A50/467 , Y02A50/58
摘要： The present invention provides methods and compositions for the treatment, prevention, or reduction of persistent infections, such as chronic infections, latent infections, and slow infections and cancer. The methods and compositions of the invention are also useful for the alleviation of one or more symptoms associated with such infections and cancer.
摘要翻译： 本发明提供了用于治疗，预防或减轻持续感染，慢性感染的方法和组合物：如，潜伏性感染，和慢性感染和癌症。 本发明的方法和组合物因此可用于与寻求感染和癌症相关的一种或多种症状的减轻有用。
-
6.发明公开Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1)pathway 有权方法和组合物持久性感染的治疗通过抑制编程1（PD-1）的-Zelltodweges
公开(公告)号：EP2397155A1
公开(公告)日：2011-12-21
申请号：EP11162667.7
申请日：2006-06-08
申请人： Dana Farber Cancer Institute , The Brigham and Women's Hospital, Inc. , Emory University , The President and Fellows of Harvard College
发明人： Freeman, Gordan , Sharpe, Arlene , Dorfman, David M. , Ahmed, Rafi , Barber, Daniel , Wherry, E. John
IPC分类号： A61K39/395 , G01N33/53 , C07K16/28
CPC分类号： C07K16/2803 , A61K31/713 , A61K38/1709 , A61K39/39 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61K2039/55516 , A61K2039/55566 , A61K2039/572 , C07K16/2818 , C07K16/2827 , C07K2317/70 , C07K2317/73 , C07K2317/74 , C07K2317/76 , C12N15/1138 , C12N2310/14 , G01N33/5011 , G01N33/505 , G01N33/57484 , G01N33/57492 , G01N2800/26 , Y02A50/412 , Y02A50/467 , Y02A50/58
摘要： The present invention provides methods and compositions for the treatment, prevention, or reduction of persistent infections, such as chronic infections, latent infections, and slow infections and cancer. The methods and compositions of the invention are also useful for the alleviation of one or more symptoms associated with such infections and cancer.
摘要翻译： 本发明提供了用于治疗，预防或减轻持续感染，慢性感染的方法和组合物：如，潜伏性感染，和慢性感染和癌症。 本发明的方法和组合物因此可用于与寻求感染和癌症相关的一种或多种症状的减轻有用。
-
公开(公告)号：EP3064220A3
公开(公告)日：2016-12-07
申请号：EP16160525.8
申请日：2007-12-26
申请人： Emory University , Dana-Farber Cancer Institute, Inc. , President and Fellows of Harvard College
发明人： Ahmed, Rafi , Freeman, Gordon , Sharpe, Arlene , Amara, Rama
摘要： PD-1 antagonists are disclosed that can be used to reduce the expression or activity of PD-1 in a subject. An immune response specific to an infectious agent or to tumor cells can be enhanced using these PD-1 antagonists in conjunction with an antigen from the infectious agent or tumor. Thus, subjects with infections, such as persistent infections can be treated using PD-1 antagonists. In additions, subjects with tumors can be treated using the PD-1 antagonists. In several examples, subjects can be treated by transplanting a therapeutically effective amount of activated T cells that recognize an antigen of interest and by administering a therapeutically effective amount of a PD-1 antagonist.
摘要翻译： 公开了可用于降低受试者中PD-1的表达或活性的PD-1拮抗剂。 使用这些PD-1拮抗剂连同来自感染剂或肿瘤的抗原，可以增强对感染因子或肿瘤细胞特异性的免疫应答。 因此，可以使用PD-1拮抗剂治疗感染例如持续感染的受试者。 此外，可以使用PD-1拮抗剂治疗患有肿瘤的受试者。 在几个实例中，可以通过移植治疗有效量的识别感兴趣抗原的活化T细胞并通过施用治疗有效量的PD-1拮抗剂来治疗受试者。
-
公开(公告)号：EP3064220B1
公开(公告)日：2020-07-22
申请号：EP16160525.8
申请日：2007-12-26
申请人： Emory University , Dana-Farber Cancer Institute, Inc. , President and Fellows of Harvard College
发明人： Ahmed, Rafi , Freeman, Gordon , Sharpe, Arlene , Amara, Rama
-
公开(公告)号：EP2133365B1
公开(公告)日：2017-05-17
申请号：EP09166886.3
申请日：2007-12-26
申请人： Emory University , Dana-Farber Cancer Institute, Inc. , President and Fellows of Harvard College
发明人： Ahmed, Rafi , Freeman, Gordon , Sharpe, Arlene , Amara, Rama
CPC分类号： C07K16/2827 , A61K39/12 , A61K39/395 , A61K2039/505 , A61K2039/507 , A61K2039/5158 , A61K2039/5256 , C07K16/2818 , C12N2710/24143 , C12N2740/16011 , C12N2760/10011 , C12N2760/10034 , C12N2770/24211 , A61K2300/00
摘要： PD-1 antagonists are disclosed that can be used to reduce the expression or activity of PD-1 in a subject. An immune response specific to an infectious agent or to tumor cells can be enhanced using these PD-1 antagonists in conjunction with an antigen from the infectious agent or tumor. Thus, subj ects with infections, such as persistent infections can be treated using PD-1 antagonists. In additions, subjects with tumors can be treated using the PD-1 antagonists. In several examples, subjects can be treated by transplanting a therapeutically effective amount of activated T cells that recognize an antigen of interest and by administering a therapeutically effective amount of a PD-1 antagonist.
摘要翻译： 公开了可用于降低受试者中PD-1的表达或活性的PD-1拮抗剂。 使用这些PD-1拮抗剂连同来自感染剂或肿瘤的抗原，可以增强对感染因子或肿瘤细胞特异性的免疫应答。 因此，可以使用PD-1拮抗剂治疗感染如持续性感染的对象。 此外，可以使用PD-1拮抗剂治疗患有肿瘤的受试者。 在几个实例中，可以通过移植治疗有效量的识别感兴趣抗原的活化T细胞并通过施用治疗有效量的PD-1拮抗剂来治疗受试者。
-
公开(公告)号：EP2133365A3
公开(公告)日：2010-01-06
申请号：EP09166886.3
申请日：2007-12-26
申请人： Emory University , DANA-FARBER CANCER INSTITUTE, INC. , President and Fellows of Harvard College
发明人： Ahmed, Rafi , Freeman, Gordon , Sharpe, Arlene , Amara, Rama
CPC分类号： C07K16/2827 , A61K39/12 , A61K39/395 , A61K2039/505 , A61K2039/507 , A61K2039/5158 , A61K2039/5256 , C07K16/2818 , C12N2710/24143 , C12N2740/16011 , C12N2760/10011 , C12N2760/10034 , C12N2770/24211 , A61K2300/00
摘要： PD-1 antagonists are disclosed that can be used to reduce the expression or activity of PD-1 in a subject. An immune response specific to an infectious agent or to tumor cells can be enhanced using these PD-1 antagonists in conjunction with an antigen from the infectious agent or tumor. Thus, subj ects with infections, such as persistent infections can be treated using PD-1 antagonists. In additions, subjects with tumors can be treated using the PD-1 antagonists. In several examples, subjects can be treated by transplanting a therapeutically effective amount of activated T cells that recognize an antigen of interest and by administering a therapeutically effective amount of a PD-1 antagonist.
-
-
-
-
-
-
-
-
-
搜索结果
13 条记录 (耗时 0.035 秒)
